These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
198 related articles for article (PubMed ID: 26837173)
1. [In vitro targeting effect of lactoferrin modified PEGylated liposomes for hepatoma cells]. Wei MY; Zou Q; Wu CB; Xu YH Yao Xue Xue Bao; 2015 Oct; 50(10):1272-9. PubMed ID: 26837173 [TBL] [Abstract][Full Text] [Related]
2. Lactoferrin-modified PEGylated liposomes loaded with doxorubicin for targeting delivery to hepatocellular carcinoma. Wei M; Guo X; Tu L; Zou Q; Li Q; Tang C; Chen B; Xu Y; Wu C Int J Nanomedicine; 2015; 10():5123-37. PubMed ID: 26316745 [TBL] [Abstract][Full Text] [Related]
3. Hepatocellular carcinoma targeting effect of PEGylated liposomes modified with lactoferrin. Wei M; Xu Y; Zou Q; Tu L; Tang C; Xu T; Deng L; Wu C Eur J Pharm Sci; 2012 Jun; 46(3):131-41. PubMed ID: 22369856 [TBL] [Abstract][Full Text] [Related]
4. A novel lactoferrin-modified stealth liposome for hepatoma-delivery of triiodothyronine. Pireddu R; Pibiri M; Valenti D; Sinico C; Fadda AM; Simbula G; Lai F Int J Pharm; 2018 Feb; 537(1-2):257-267. PubMed ID: 29294323 [TBL] [Abstract][Full Text] [Related]
5. Design of cholesterol arabinogalactan anchored liposomes for asialoglycoprotein receptor mediated targeting to hepatocellular carcinoma: In silico modeling, in vitro and in vivo evaluation. Pathak P; Dhawan V; Magarkar A; Danne R; Govindarajan S; Ghosh S; Steiniger F; Chaudhari P; Gopal V; Bunker A; Róg T; Fahr A; Nagarsenker M Int J Pharm; 2016 Jul; 509(1-2):149-158. PubMed ID: 27231122 [TBL] [Abstract][Full Text] [Related]
6. Fabrication of Imatinib Mesylate-Loaded Lactoferrin-Modified PEGylated Liquid Crystalline Nanoparticles for Mitochondrial-Dependent Apoptosis in Hepatocellular Carcinoma. Nisha R; Kumar P; Kumar U; Mishra N; Maurya P; Singh S; Singh P; Guleria A; Saha S; Saraf SA Mol Pharm; 2021 Mar; 18(3):1102-1120. PubMed ID: 33356314 [TBL] [Abstract][Full Text] [Related]
7. Cholesterol anchored arabinogalactan for asialoglycoprotein receptor targeting: synthesis, characterization, and proof of concept of hepatospecific delivery. Pathak PO; Nagarsenker MS; Barhate CR; Padhye SG; Dhawan VV; Bhattacharyya D; Viswanathan CL; Steiniger F; Fahr A Carbohydr Res; 2015 May; 408():33-43. PubMed ID: 25841057 [TBL] [Abstract][Full Text] [Related]
8. Liposomes for targeting hepatocellular carcinoma: use of conjugated arabinogalactan as targeting ligand. Shah SM; Goel PN; Jain AS; Pathak PO; Padhye SG; Govindarajan S; Ghosh SS; Chaudhari PR; Gude RP; Gopal V; Nagarsenker MS Int J Pharm; 2014 Dec; 477(1-2):128-39. PubMed ID: 25311181 [TBL] [Abstract][Full Text] [Related]
9. Targeting effect of PEGylated liposomes modified with the Arg-Gly-Asp sequence on gastric cancer. Ding J; Feng M; Wang F; Wang H; Guan W Oncol Rep; 2015 Oct; 34(4):1825-34. PubMed ID: 26238930 [TBL] [Abstract][Full Text] [Related]
11. Lactoferrin-modified procationic liposomes as a novel drug carrier for brain delivery. Chen H; Tang L; Qin Y; Yin Y; Tang J; Tang W; Sun X; Zhang Z; Liu J; He Q Eur J Pharm Sci; 2010 May; 40(2):94-102. PubMed ID: 20298779 [TBL] [Abstract][Full Text] [Related]
12. Transporter occluded-state conformation-induced endocytosis: Amino acid transporter ATB Luo Q; Gong P; Sun M; Kou L; Ganapathy V; Jing Y; He Z; Sun J J Control Release; 2016 Dec; 243():370-380. PubMed ID: 27810556 [TBL] [Abstract][Full Text] [Related]
13. Hepatocellular carcinoma-targeted effect of configurations and groups of glycyrrhetinic acid by evaluation of its derivative-modified liposomes. Sun Y; Dai C; Yin M; Lu J; Hu H; Chen D Int J Nanomedicine; 2018; 13():1621-1632. PubMed ID: 29588589 [TBL] [Abstract][Full Text] [Related]
14. PEGylation potentiates hepatoma cell targeted liposome-mediated in vitro gene delivery via the asialoglycoprotein receptor. Mkhwanazi NK; de Koning CB; van Otterlo WAL; Ariatti M; Singh M Z Naturforsch C J Biosci; 2017 Jul; 72(7-8):293-301. PubMed ID: 28063265 [TBL] [Abstract][Full Text] [Related]
15. Asialoglycoprotein receptor-targeted liposomes loaded with a norcantharimide derivative for hepatocyte-selective targeting. Liu X; Han M; Xu J; Geng S; Zhang Y; Ye X; Gou J; Yin T; He H; Tang X Int J Pharm; 2017 Mar; 520(1-2):98-110. PubMed ID: 28167263 [TBL] [Abstract][Full Text] [Related]
16. Folate receptor-targeted liposomes loaded with a diacid metabolite of norcantharidin enhance antitumor potency for H22 hepatocellular carcinoma both in vitro and in vivo. Liu MC; Liu L; Wang XR; Shuai WP; Hu Y; Han M; Gao JQ Int J Nanomedicine; 2016; 11():1395-412. PubMed ID: 27110110 [TBL] [Abstract][Full Text] [Related]
17. N-acetylgalactosamine-decorated nanoliposomes for targeted delivery of paclitaxel to hepatocellular carcinoma. Li T; Yu P; Chen Y; Sun B; Dong P; Zhu T; Meng X Eur J Med Chem; 2021 Oct; 222():113605. PubMed ID: 34126457 [TBL] [Abstract][Full Text] [Related]
18. Hepatoma-targeting and pH-sensitive nanocarriers based on a novel D-galactopyranose copolymer for efficient drug delivery. Ding Y; Han J; Tian B; Han J; Zhang J; Zheng H; Han Y; Pei M Int J Pharm; 2014 Dec; 477(1-2):187-96. PubMed ID: 25455771 [TBL] [Abstract][Full Text] [Related]
19. Lactoferrin-modified PEG-co-PCL nanoparticles for enhanced brain delivery of NAP peptide following intranasal administration. Liu Z; Jiang M; Kang T; Miao D; Gu G; Song Q; Yao L; Hu Q; Tu Y; Pang Z; Chen H; Jiang X; Gao X; Chen J Biomaterials; 2013 May; 34(15):3870-81. PubMed ID: 23453061 [TBL] [Abstract][Full Text] [Related]
20. Self-assembled polymersomes conjugated with lactoferrin as novel drug carrier for brain delivery. Yu Y; Pang Z; Lu W; Yin Q; Gao H; Jiang X Pharm Res; 2012 Jan; 29(1):83-96. PubMed ID: 21979908 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]